The global lung cancer screening market is set to witness a robust growth period on account of the rising prevalence of lung cancer across the globe. The International Agency for Research on Cancer (IARC) states that lung cancer is the leading type of cancer, causing 1.8 million deaths in 2018. A study published in the World Cancer Research Journal reveals that by 2040, the number of people affected by lung cancer will increase to 3,610,896, with the incidence rate being greater in men than women. This trend is expected to continue in the foreseeable future as pollution levels rise, especially in developing countries. Higher pollution levels would cause greater emission of toxins, thereby fuelling the global lung cancer screening market growth during the forecast period.

Fortune Business Insights, in its report, titled “Lung Cancer Screening Market Size, Share and Global Trend By Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Others), By Diagnosis Type (Low-Dose Spiral CT Scan, Chest X-Ray, Sputum Cytology), By End User (Hospitals, Oncology Clinics, Diagnostics Centers) and Geography Forecast till 2032”, provides an in-depth evaluation of the forces that will influence the market in the stipulated period. The report also highlights the possible trends that could emerge and the dynamics that will shape the market.

The global lung cancer screening market size was valued at USD 3.28 billion in 2023. The market is projected to grow from USD 3.55 billion in 2024 to USD 7.10 billion by 2032, exhibiting a CAGR of 9.1% during the forecast period.

Lung cancer is a type of cancer that causes cells to multiply uncontrollably in the lungs. Since lungs are the central organs of the human respiratory system, lung cancer severely diminishes a person’s ability to breathe. Its most common type is the non-small cell lung cancer, accounting for around 85% of lung cancer cases.

Increasing Consumption of Tobacco to Favour Market Growth

According to WHO statistics, consumption of tobacco kills approximately 8 million every year. Out of these, 1.2 million die due to second-hand or passive smoking. Currently, close to 1.1 billion people in the world indulge in smoking. The Centres for Disease Control and Prevention (CDC) found that around 85% of lung cancer deaths are caused by cigarette smoking in the US. Many other studies have found unequivocal links between tobacco smoking and lung cancer. Thus, growing smoking rates is likely to increase the prevalence of lung cancer and raise the demand for lung cancer screening equipment and drugs. The IARC also identifies poor diagnosis and prognosis of lung cancer as one of the leading causes of lung cancer deaths worldwide. This factor can aid in expanding the global lung cancer screening market size during the forecast period.

Rapidly Rising Pollution Levels to Boost the Market

Industries and vehicles emit toxic gases such as carbon monoxide and particulate matter which have been classified as carcinogenic by the IARC. Carbon emitted from coal burning is also known to cause cancer. Therefore, rising pollution levels, especially in developing nations, represents excellent sales opportunities for lung cancer screening technologies, fuelling the global lung cancer screening market revenue.

Large Smoking Population to Thrust the Market in North America Upwards

North America is expected to hold a dominant section of the global lung cancer screening market share, primarily owing to the large number of smokers in the region. Additionally, a rising geriatric population and strong healthcare infrastructure are the other important drivers for the market in North America. In Asia-Pacific, large scale tobacco consumption and increasing pollution and population levels will drive the market in the region.

Thermo Fisher’s Oncomine Dx Target Test Gets Green Light from Japanese Government

US-based Thermo Fisher Scientific Inc. got the approval from the Japanese Ministry of Health in June 2019 to launch its next-generation sequencing-based Oncomine Dx Target Test CDx System to treat non-small cell lung cancer. Such approvals from foreign authorities is expected to spruce up innovation energies of companies in the global lung cancer screening market. Some players are also doubling down their R&D activities. For example, WVU Cancer Institute introduced a low-dose lung cancer screening mobile CT in West Virginia in July 2018.

Some of the key participants in the global lung cancer screening market include:

  • Illumina Inc.
  • Thermo Fisher Scientific
  • AstraZeneca
  • Hoffmann-Le Roche Ltd
  • Jansenn Pharmaceuticals, Inc.
  • Abbott
  • Agilent Technologies, Inc.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower, Baner-Mahalunge Road,
Baner, Pune-411045, Maharashtra, India.

Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]

Fortune Business Insights™

Linkedin | Twitter | Blogs

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]